Genmab A/S or Lantheus Holdings, Inc.: Who Leads in Yearly Revenue?

Genmab A/S Dominates Revenue Growth Over Lantheus Holdings

__timestamp	Genmab A/S	Lantheus Holdings, Inc.
Wednesday, January 1, 2014	850385000	301600000
Thursday, January 1, 2015	1133041000	293461000
Friday, January 1, 2016	1816122000	301853000
Sunday, January 1, 2017	2365436000	331378000
Monday, January 1, 2018	3025137000	343374000
Tuesday, January 1, 2019	5366000000	347337000
Wednesday, January 1, 2020	10111000000	339410000
Friday, January 1, 2021	8482000000	425208000
Saturday, January 1, 2022	14595000000	935061000
Sunday, January 1, 2023	16474000000	1296429000
Monday, January 1, 2024	21526000000

Data in motion

Revenue Race: Genmab A/S vs. Lantheus Holdings, Inc.

In the competitive landscape of biotechnology and pharmaceuticals, revenue growth is a key indicator of success. Over the past decade, Genmab A/S has consistently outpaced Lantheus Holdings, Inc. in annual revenue. Starting in 2014, Genmab's revenue was nearly three times that of Lantheus, and by 2023, it had surged to over 12 times more. This remarkable growth trajectory highlights Genmab's strategic advancements and market positioning. In contrast, Lantheus has shown steady, albeit modest, growth, with its revenue increasing by approximately 330% over the same period. The data underscores Genmab's dominance in the sector, driven by innovative therapies and strategic partnerships. As the industry evolves, these companies' financial performances will continue to be a focal point for investors and analysts alike.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025